Parliamentary Exchange on the NHS and Drugs – Answered 21st March 2017

Rt Hon Stephen Timms MP for East Ham asked the Secretary of State for Health, pursuant to the Answer of 23 January 2017 to Question 60583, on NHS: drugs, if he will publish those initial assessments.

To which Nicola Blackwood MP for Oxford West and Abingdon and Parliamentary Under-Secretary (Department of Health) replied:

Flexible pricing is an option for companies within the 2014 Pharmaceutical Price Regulation Scheme (PPRS). To date, no applications have been received under the flexible pricing provisions since their introduction under the 2009 PPRS.

The PPRS pricing flexibility provisions make clear that the Government is unlikely to support proposals for pricing approaches that would result in indication-specific pricing. This is because initial assessments indicate that such approaches would have significant long-term financial and operational implications for the National Health Service

To read more about this, please click here.

Rt Hon Stephen Timms MP for East Ham’s question referred to Nicola Blackwood’s response on 23rd January when Stephen Timms asked the Secretary of State for Health, what assessment he has made of the potential for (a) flexible pricing and (b) indication-specific pricing for drug purchase by the NHS.

To which Nicola Blackwood replied:

Flexible pricing is an option for companies within the 2014 Pharmaceutical Price Regulation Scheme (PPRS). To date, no applications have been received under the flexible pricing provisions since their introduction under the 2009 PPRS.

The PPRS pricing flexibility provisions make clear that the Government is unlikely to support proposals for pricing approaches that would result in indication-specific pricing. This is because initial assessments indicate that such approaches would have significant long-term financial and operational implications for the National Health Service.

To read more about this, please click here.

Tagged with

Published on 23. March 2017 in News UK